The recently published study by Davies et al., 1 confirms previous data from our laboratory indicating that nilotinib, unlike imatinib, does not require the human organic cation transporter-1 (hOCT-1) for active transport into leukaemic cells.
2 This study also confirms our own recent data that show the predominantly passive nature of nilotinib uptake in which maximum intracellular concentrations of between 300 and 400 ng of 14 C-nilotinib per 200 000 cells are reached within the first 2 min of incubation. This peak is then followed by a rapid, temperature-sensitive, ATP-dependent decrease. Davies et al. suggest that the reduction in the intracellular concentration of imatinib in the presence of nilotinib is mediated through inhibition of the function of the OCT-1 protein.
3 This finding could have significant implications for imatinib/nilotinib combination therapies and may adversely affect the action of concomitantly administered medications transported by OCT-1 (for example, metformin). We have previously shown in primary cells and cell lines that the addition of nilotinib to 14 C-imatinib (IM) in the intracellular uptake and retention (IUR) assay resulted in a reduction in intracellular IM; however, this failed to reach statistical significance. 4 For this study, we have performed a series of combination IUR 2 and OCT-1 Activity assays 3 to assess the effect of nilotinib on OCT-1 Activity, a measure previously shown to be highly predictive of patient response. 14 C-labelled imatinib at the clinically relevant concentrations of 1 and 2 mM for 2 h at 37 1C, alone and in combination with the OCT-1-specific inhibitor prazosin (100 mM) and non-radiolabelled nilotinib (1 and 2 mM). We have defined OCT-1 Activity to be the functional activity of the OCT-1 protein involved in imatinib transport, and is determined by the difference between imatinib IUR in the absence and presence of prazosin.
3 As shown in Figure 1 , a reduction in the intracellular concentration of imatinib was again observed in patient cells in the presence of both 1 and 2 mM nilotinib. This failed to reach statistical significance at either 1 or 2 mM of imatinib. Importantly, there was also no statistically significant effect of either 1 or 2 mM nilotinib on the OCT-1 Activity for imatinib in this patient cohort (P ¼ 0.71 and 0.974, respectively). It is important to note that although the reductions seen in IM IUR on addition of prazosin and nilotinib in most patients and cell lines are not of enough magnitude to render the change statistically significant, these reductions occur consistently in every experiment performed. Interestingly, although also not significant statistically, the largest reduction in the IM concentration was in the 2 mM IM þ prazosin arm of the experiment, in which the nonprazosin-inhibitable, most likely, passive transport of imatinib is measured (Figure 1 ). To investigate this further, the same experiments were performed in K562 cells at both 37 1C (n ¼ 3) and 4 1C (n ¼ 4). At 37 1C the same changes were observed in the IUR of IM with the addition of nilotinib (Figure 2a) . Importantly, when these experiments were performed at 4 1C (Figure 2b ), a temperature believed to inhibit active OCT-1 transport, the level of IM is reduced to the same level as that observed in the 37 1C þ prazosin arm of the experiment (21.1 ng per 200 000 cells vs 19.6 ng per 200 000 cells, respectively). Furthermore, at 4 1C there was an additional reduction in the intracellular concentration of imatinib in the Letters to the Editor presence of nilotinib at 1 and 2 mM (14.4 and 13.9 ng per 200 000 cells, respectively). This suggests that the effect of nilotinib is mediated through passive, and not active, ATP-dependent mechanisms. There was no measurable effect of prazosin at 4 1C as would be anticipated. Hence, although we do agree, and have previously shown that nilotinib results in a reduced, but not statistically significant decrease in the intracellular concentration of imatinib, we find no evidence to suggest that this is mediated through OCT-1 or any other active process.
To further investigate this, we also recapitulated the experiments of Davies et al., which suggested that higher concentrations of nilotinib (4 mM) reduced the uptake of the hOCT-1 substrate, Tetraethylammonium Bromide (TEA), and abolished imatinib uptake. However, we were unable to show any significant effects of 4 mM nilotinib on the intracellular concentrations of imatinib in either KCL22 or K562 cells (n ¼ 3) (Table 1a) . Similarly, 4 mM nilotinib also had no significant effect on the uptake of TEA (5 mM; n ¼ 4 and 10 mM; n ¼ 2) in K562 cells (Table 1b) .
In agreement with these data, Davies et al. also did not see a significant reduction of TEA levels at the 2-h time point in the presence of nilotinib. Thus, we do not concur that 'drugs transported by hOCT-1 (for example, imatinib, metformin) would be blocked when co-administered with nilotinib'. Furthermore, as hOCT-1 is known to have a large extracellular substrate-binding domain, it is not possible to infer from the experiments with one hOCT-1 substrate a universal effect on all substrates. The interaction of different substrates must be independently assessed as binding regions within the extracellular domain may not overlap or interact, as shown by our differing results for imatinib and TEA.
In summary, we describe a reduction in the level of IM in the presence of both 1 and 2 mM nilotinib; however, this reduction fails to reach statistical significance. Furthermore, we show that there is no significant effect on the functional activity of the hOCT-1 protein mediated by nilotinib, and provide no evidence for nilotinib being an hOCT-1 inhibitor at clinically relevant concentrations. We do, however, show that in the presence of nilotinib, there is a reduction in the non-prazosin-inhibitable imatinib uptake, suggesting that nilotinib may interfere with the passive uptake of imatinib. These results are confirmed by our experiments at 4 1C. As nilotinib has increased lipophilicity when compared with imatinib, this is a possible explanation for our observations as nilotinib is more likely to be trapped in the membrane and sterically hinder the passive import of imatinib. Thus, we find no evidence to suggest that nilotinib is an inhibitor of OCT-1, or that in combination, nilotinib would result in significant reductions in the intracellular concentration of drugs such as imatinib, which are transported through OCT-1. This is an important finding as we move into the era of customized therapeutics in chronic myeloid leukaemia.
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Deborah White and Timothy Hughes receive honoraria and research funds from Novartis Pharmaceuticals, and are members of the Advisory Boards for Novartis. However, Novartis had no role in the design of the study, collection and analysis of data nor the decision to publish. Laura Eadie has no conflict of interest to disclose. 2 In approximately 90% of CBFB-MYH11-positive cases, the break points cluster downstream in MYH11, whereas in the remaining cases they are located more upstream (Figure 1) . By analyzing genomic inv(16) break points, we observed that the MYH11 gene partly overlaps with the NDE1 (nuclear distribution gene E homolog 1) gene. NDE1 and MYH11 are transcribed from opposing DNA strands and at their 3 0 ends the genes overlap at the genomic, transcript as well as coding level (Figure 1) . Interestingly, the frequently occurring downstream break points in MYH11 are located between NDE1 exons 7 and 8. This indicates that these break points disrupt NDE1 coding sequences in addition to MYH11. The break points in NDE1 predict the formation of a truncated protein that lacks the last 19 carboxy terminal amino acids (Figure 1 ). Upstream MYH11 break points do not disrupt NDE1 coding sequences but may disrupt the NDE1 gene in its non-coding part as it is unknown how far NDE1 extends at the 3 0 end (Figure 1 ). These findings indicate that in addition to CBFB and MYH11, NDE1 is disrupted in at least 90% of cases with inv(16)-positive AML.
MYH11 is weakly expressed in normal and inv(16)-negative AML bone marrow samples. In contrast, a significantly higher expression of the relevant MYH11 moiety is observed in all inv(16)-positive cases, due to the fusion to CBFB. Figure 1 NDE1 is disrupted in 90% of cases with AML and an inv(16). MYH11 and NDE1 are transcribed from overlapping opposing DNA strands. MYH11 exons (black boxes) were identified by comparing the full-length MYH11 transcript with chromosome 16 MYH11 BAC clones (GenBank accession numbers NM_022844 and NT_chrom16). NDE1 exons were identified similarly. The last 11 exons of MYH11 (exons 32-42) are located within the last intron of NDE1, whereas MYH11 exons 29, 30 and 31 almost completely overlap with the most 3 0 exon (exon 8) of NDE1 (total overlap of 477 bp). Downstream MYH11 breakpoints disrupt NDE1 coding sequences, whereas upstream break points (present in 10% of inv(16) cases) do not. Upstream break points may still disrupt the NDE1 gene as it is not known how far NDE1 extends at the 3 0 end. Asterisk indicates NDE1 stop codon. Approximately 88% of genomic break points occur between MYH11 exons 32 and 33.
